FDA Approves GE Healthcare Breast Imaging With 3D Tomosynthesis Solution Yielding 3D Images Using X-ray Radiation Equivalent To 2D Scans

FDA Approves GE Healthcare Breast Imaging With 3D Tomosynthesis Solution Yielding 3D Images Using X-ray Radiation Equivalent To 2D Scans
SenoClaireGE Healthcare has announced that they have received FDA approval of SenoClaire, GE's new breast tomosynthesis solution designed with a novel three-dimensional approach to imaging technology. Working with Massachusetts General Hospital, GE developed SenoClaire technology to use a short, low-dose X-ray sweep that moves around a positioned breast and features 9 exposures that are acquired through a unique step-and-shoot approach, which removes any potential motion from the tube that in turn helps to significantly reduce blurry imaging while increasing image sharpness.

GE Seeks to Advance Breast Cancer Screening senoclairepatient

Despite the progress that has been made over the past years in advancing mammography technology, GE Healthcare notes that an estimated 20 percent or more of breast cancers are still missed when using digital mammograms. One major reason for the inaccuracies is that cancer can be obscured by normal tissues within the breast. Additionally, normal tissues located in different parts of the breast may become superimposed in the imaging, thus gen
Subscribe or to access all post and page content.